Actinium Pharmaceuticals Stock Analysis
ATNM Stock | USD 7.06 0.10 1.44% |
Actinium Pharmaceuticals is overvalued with Real Value of 6.64 and Target Price of 27.6. The main objective of Actinium Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Actinium Pharmaceuticals is worth, separate from its market price. There are two main types of Actinium Pharmaceuticals' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Actinium Pharmaceuticals' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Actinium Pharmaceuticals' stock to identify patterns and trends that may indicate its future price movements.
The Actinium Pharmaceuticals stock is traded in the USA on NYSE MKT Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Actinium Pharmaceuticals is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Actinium Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Actinium Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
Actinium |
Actinium Stock Analysis Notes
About 25.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.83. Actinium Pharmaceuticals last dividend was issued on the 11th of August 2020. The entity had 1:30 split on the 11th of August 2020. Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. The company was incorporated in 2000 and is based in New York, New York. Actinium Pharmaceuticals operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 32 people. For more info on Actinium Pharmaceuticals please contact Kaushik Dave at 646 677 3870 or go to https://www.actiniumpharma.com.Actinium Pharmaceuticals Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Actinium Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Actinium Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Actinium Pharmaceuticals is way too risky over 90 days horizon | |
Actinium Pharmaceuticals appears to be risky and price may revert if volatility continues | |
The company reported the previous year's revenue of 81 K. Net Loss for the year was (48.82 M) with profit before overhead, payroll, taxes, and interest of 1.03 M. | |
Actinium Pharmaceuticals currently holds about 116.33 M in cash with (47.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.62. | |
Latest headline from MacroaxisInsider: Acquisition by Mark Berger of 400000 shares of Actinium Pharmaceuticals at 0.232 subject to Rule 16b-3 |
Actinium Pharmaceuticals Upcoming and Recent Events
Earnings reports are used by Actinium Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Actinium Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
1st of April 2024 Upcoming Quarterly Report | View | |
20th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
1st of April 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Actinium Largest EPS Surprises
Earnings surprises can significantly impact Actinium Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2021-07-30 | 2021-06-30 | -0.3 | -0.25 | 0.05 | 16 | ||
2022-03-25 | 2021-12-31 | -0.3 | -0.36 | -0.06 | 20 | ||
2023-03-31 | 2022-12-31 | -0.35 | -0.43 | -0.08 | 22 |
Actinium Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 204.6 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Actinium Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Actinium Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Actinium Profitablity
Actinium Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Actinium Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Actinium Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Actinium Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Actinium Pharmaceuticals' profitability requires more research than a typical breakdown of Actinium Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.60) | (0.57) | |
Return On Capital Employed | (0.71) | (0.68) | |
Return On Assets | (0.60) | (0.57) | |
Return On Equity | (1.34) | (1.27) |
Management Efficiency
Actinium Pharmaceuticals has return on total asset (ROA) of (0.3317) % which means that it has lost $0.3317 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9492) %, meaning that it created substantial loss on money invested by shareholders. Actinium Pharmaceuticals' management efficiency ratios could be used to measure how well Actinium Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to grow to -0.57. In addition to that, Return On Capital Employed is likely to grow to -0.68. At this time, Actinium Pharmaceuticals' Total Assets are very stable compared to the past year. As of the 24th of April 2024, Total Current Assets is likely to grow to about 82.2 M, though Non Currrent Assets Other are likely to grow to (0.95).Last Reported | Projected for Next Year | ||
Book Value Per Share | 1.37 | 1.30 | |
Net Current Asset Value | 0.00 | 0.00 | |
Tangible Asset Value | 0.00 | 0.00 | |
Tangible Book Value Per Share | 1.37 | 1.30 | |
Enterprise Value Over EBITDA | (1.18) | (1.24) | |
Price Book Value Ratio | 3.72 | 3.90 | |
Enterprise Value Multiple | (1.18) | (1.24) | |
Price Fair Value | 3.72 | 3.90 | |
Enterprise Value | 60.6 M | 77.2 M |
The analysis of Actinium Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Actinium Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Actinium Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.076 |
Technical Drivers
As of the 24th of April, Actinium Pharmaceuticals shows the Risk Adjusted Performance of 0.0687, mean deviation of 4.36, and Downside Deviation of 4.81. Actinium Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Actinium Pharmaceuticals, which can be compared to its peers. Please confirm Actinium Pharmaceuticals variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Actinium Pharmaceuticals is priced correctly, providing market reflects its regular price of 7.06 per share. Given that Actinium Pharmaceuticals has jensen alpha of 0.5279, we suggest you to validate Actinium Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.Actinium Pharmaceuticals Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Actinium Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Actinium Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Actinium Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Actinium Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Actinium Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Actinium Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mark Berger 2 days ago Acquisition by Mark Berger of 400000 shares of Actinium Pharmaceuticals at 0.232 subject to Rule 16b-3 | ||
C Nicholson over three months ago Acquisition by C Nicholson of 70311 shares of Actinium Pharmaceuticals subject to Rule 16b-3 |
Actinium Pharmaceuticals Predictive Daily Indicators
Actinium Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Actinium Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 9222.75 | |||
Daily Balance Of Power | 0.2273 | |||
Rate Of Daily Change | 1.01 | |||
Day Median Price | 7.1 | |||
Day Typical Price | 7.09 | |||
Price Action Indicator | 0.01 | |||
Period Momentum Indicator | 0.1 |
Actinium Pharmaceuticals Corporate Filings
10K | 29th of March 2024 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
13A | 9th of February 2024 An amended filing to the original Schedule 13G | ViewVerify |
2nd of February 2024 Other Reports | ViewVerify | |
13A | 29th of January 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 29th of December 2023 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 1st of December 2023 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
9th of November 2023 Other Reports | ViewVerify | |
10Q | 2nd of November 2023 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Actinium Pharmaceuticals Forecast Models
Actinium Pharmaceuticals' time-series forecasting models are one of many Actinium Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Actinium Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Actinium Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Actinium Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Actinium shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Actinium Pharmaceuticals. By using and applying Actinium Stock analysis, traders can create a robust methodology for identifying Actinium entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (602.69) | (572.56) | |
Operating Profit Margin | (640.99) | (608.94) | |
Net Loss | (693.10) | (658.44) | |
Gross Profit Margin | (8.75) | (8.32) |
Current Actinium Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Actinium analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Actinium analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
27.6 | Strong Buy | 6 | Odds |
Most Actinium analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Actinium stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Actinium Pharmaceuticals, talking to its executives and customers, or listening to Actinium conference calls.
Actinium Stock Analysis Indicators
Actinium Pharmaceuticals stock analysis indicators help investors evaluate how Actinium Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Actinium Pharmaceuticals shares will generate the highest return on investment. By understating and applying Actinium Pharmaceuticals stock analysis, traders can identify Actinium Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow | 109.3 M | |
Common Stock Shares Outstanding | 26.6 M | |
Total Stockholder Equity | 36.4 M | |
Property Plant And Equipment Net | 2.9 M | |
Cash And Short Term Investments | 76.7 M | |
Cash | 76.7 M | |
Accounts Payable | 8 M | |
Net Debt | -74.6 M | |
50 Day M A | 7.7014 | |
Total Current Liabilities | 8.5 M | |
Other Operating Expenses | 52 M | |
Non Current Assets Total | 3.2 M | |
Forward Price Earnings | 6.8399 | |
Non Currrent Assets Other | -1.00 | |
Stock Based Compensation | 3.8 M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for Actinium Stock analysis
When running Actinium Pharmaceuticals' price analysis, check to measure Actinium Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Actinium Pharmaceuticals is operating at the current time. Most of Actinium Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Actinium Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Actinium Pharmaceuticals' price. Additionally, you may evaluate how the addition of Actinium Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |
Is Actinium Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.83) | Revenue Per Share 0.003 | Quarterly Revenue Growth (1.00) | Return On Assets (0.33) | Return On Equity (0.95) |
The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Actinium Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.